Merck Hits Back At Halozyme In Cancer Drug Patent Row
Merck has once again asked a London court to nix Halozyme's patents for an under-the-skin drug delivery system because they allegedly solve no technical problem in the field, as it plans...To view the full article, register now.
Already a subscriber? Click here to view full article